Observational Study of Clinical Practice in Patients with Pancreatic Adenocarcinoma in Greece

Table 8

Overall and progression-free survival according to second-line chemotherapy regimen in the overall population and the group of patients diagnosed during study enrolment.

	Overall population			Diagnosed during enrolment
	Median	95% CI	value	Median	95% CI	value
OS (months)
Nab-paclitaxel-gemcitabine	8.3	6.0–10.7	0.785	7.5	6.1–8.9	0.751
FOLFIRINOX/CAPOXIRI	13.4	5.8–21.0		11.8	4.3–19.3
FOLFOX/CAPOX	7.6	6.5–8.8		7.6	1.8–13.4
Other regimens	8.9	5.2–12.6		6.5	2.7–10.2
PFS (months)
Nab-paclitaxel-gemcitabine	4.5	3.7–5.3	0.194	4.5	3.6–5.4	0.584
FOLFIRINOX/CAPOXIRI	8.0	6.4–9.6		6.9	0.5–13.3
Gemcitabine	4.9	2.8–7.0		4.4	1.6–7.2
Other regimens	6.3	4.4–8.3		6.1	2.2–9.9

CAPOXIRI, oxaliplatin/irinotecan/capecitabine; 95% CI, 95% confidence intervals; FOLFIRINOX, oxaliplatin/irinotecan/leucovorin/5-fluorouracil; OS, overall survival; PFS; progression-free survival.